6852 Personalised medicine for the treatment of asthma in young people: reporting adolescents views

Objectives There is increasing evidence to support the use of personalised medicine-led prescribing in young people's asthma. However, there is limited knowledge on the views of young people with respect to the motivation and acceptability for genotype directed therapy. Methods Young people aged 12–18 years old participating in the PACT pragmatic randomised controlled trial assessing asthma prescribing according to Arg16Gly β2 adrenoceptor genotype¹ completed online questionnaires exploring their views on personalised medicine. Results 241 online questionnaires were distributed to adolescents who participated in the PACT trial and 186 questionnaires were returned (response rate 77.2%). The majority were happy to be approached to participate in this trial (n = 185, 99.4%). There was almost unanimous agreement that asthma control improved over the course of the study irrespective of the trial arm (n = 185, 99.4%). The majority believed that asthma research would help doctors understand and treat asthma better (n = 181, 97.3%). A small minority had concerns about the use and storage of their DNA for research (n = 12, 6.4%). 36 participants (19.4%) had concerns about having to stop or change their asthma medication. The most important motivating factor was attributed to believing the study would benefit other patients in future (n = 97, 52.2%), followed by curiosity regarding their genetic type and best treatment for asthma (n = 32, 17.2%). Very few had key motivating factors of receiving better care by taking part (n = 1, 0.5%), for closer monitoring (n= 2, 1.1%) or because they thought their asthma would get worse unless they took part (n = 1, 0.5%). Conclusion Adolescents find personalised medicine based asthma treatment trials to be largely acceptable without major concerns regarding the use and storage of DNA for research. The key motivating factor was altruism. The majority felt their asthma improved, which may be attributed to the trial effect. It would be beneficial to investigate parental views and views of communities from different geographical locations, and ethnic and socioeconomic groups. Reference Ruffles, et al. Asthma prescribing according to Arg16Gly beta-2 genotype: a randomised trial in adolescents, European Respiratory Journal, 2021.